131 related articles for article (PubMed ID: 3044323)
1. The Republic of Singapore Navy's Scopoderm TTS study: results after 2,200 man-days at sea.
How J; Lee PS; Seet LC; Tan PK
Aviat Space Environ Med; 1988 Jul; 59(7):646-50. PubMed ID: 3044323
[TBL] [Abstract][Full Text] [Related]
2. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
Attias J; Gordon C; Ribak J; Binah O; Rolnick A
Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
[TBL] [Abstract][Full Text] [Related]
4. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
[TBL] [Abstract][Full Text] [Related]
5. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
Noy S; Shapira S; Zilbiger A; Ribak J
Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
[TBL] [Abstract][Full Text] [Related]
6. Effect of transdermally administered scopolamine in preventing motion sickness.
McCauley ME; Royal JW; Shaw JE; Schmitt LG
Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness.
Pingree BJ; Pethybridge RJ
Aviat Space Environ Med; 1994 Jul; 65(7):597-605. PubMed ID: 7945125
[TBL] [Abstract][Full Text] [Related]
8. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study.
Gil A; Nachum Z; Tal D; Shupak A
Clin Neuropharmacol; 2012; 35(1):37-9. PubMed ID: 22139622
[TBL] [Abstract][Full Text] [Related]
9. INM investigations into drugs for seasickness prophylaxis.
Pingree BJ
J R Nav Med Serv; 1994; 80(2):76-80. PubMed ID: 7707278
[TBL] [Abstract][Full Text] [Related]
10. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
[TBL] [Abstract][Full Text] [Related]
11. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
Graybiel A; Knepton J; Shaw J
Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
[TBL] [Abstract][Full Text] [Related]
12. Transdermal scopolamine in the prevention of motion sickness at sea.
Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
[TBL] [Abstract][Full Text] [Related]
13. Control of simulator sickness in an AH-64 aviator.
Kroll JD
Aviat Space Environ Med; 1989 Dec; 60(12):1202-3. PubMed ID: 2604677
[TBL] [Abstract][Full Text] [Related]
14. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
[TBL] [Abstract][Full Text] [Related]
15. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
[TBL] [Abstract][Full Text] [Related]
16. Transderm scopolamine efficacy related to time of application prior to the onset of motion.
Levy GD; Rapaport MH
Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572
[TBL] [Abstract][Full Text] [Related]
17. Transdermal scopolamine use for post-rhytidectomy sialocele.
Lapid O; Kreiger Y; Sagi A
Aesthetic Plast Surg; 2004; 28(1):24-8. PubMed ID: 15116278
[TBL] [Abstract][Full Text] [Related]
18. Scopolamine bioavailability in combined oral and transdermal delivery.
Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
[TBL] [Abstract][Full Text] [Related]
19. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
Nachum Z; Shupak A; Gordon CR
Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of antimotion sickness drugs.
Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
